216 related articles for article (PubMed ID: 20959068)
61. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
62. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.
Nisman B; Biran H; Heching N; Barak V; Ramu N; Nemirovsky I; Peretz T
Br J Cancer; 2008 Jan; 98(1):77-9. PubMed ID: 18087272
[TBL] [Abstract][Full Text] [Related]
63. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
[TBL] [Abstract][Full Text] [Related]
64. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: A meta-analysis.
Fu L; Wang R; Yin L; Shang X; Zhang R; Zhang P
Int J Biol Markers; 2019 Sep; 34(3):251-261. PubMed ID: 31436122
[TBL] [Abstract][Full Text] [Related]
65. [Significance of serum neuron-specific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer].
Chen Y; Peng W; Huang Y; Chen J; Su G; Jiang C; Xiao Y
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):508-11. PubMed ID: 26463326
[TBL] [Abstract][Full Text] [Related]
66. M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.
Chu T; Jiang L; Ying W; Han B
Clin Transl Oncol; 2017 Mar; 19(3):326-331. PubMed ID: 27468866
[TBL] [Abstract][Full Text] [Related]
67. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
[TBL] [Abstract][Full Text] [Related]
68. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
69. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
70. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
71. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
72. Reduction of Serum Cytokeratin-3A9 is Associated with Chemotherapeutic Response in Patients with Non-Small Cell Lung Cancer.
Shi GL; Wu ED; Sun Y; Yin YJ; Song CX
Clin Lab; 2015; 61(5-6):497-504. PubMed ID: 26118182
[TBL] [Abstract][Full Text] [Related]
73. A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer.
Kagohashi K; Satoh H; Ishikawa H; Ohtsuka M; Sekizawa K
Med Oncol; 2008; 25(2):187-9. PubMed ID: 17968682
[TBL] [Abstract][Full Text] [Related]
74. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
75. The clinical value of new tumor biomarker cytokeratin 2G2 detection in non-small cell lung cancer patients.
Liang ZK; Yin YJ; Wu ED; Shi GL
Clin Lab; 2013; 59(5-6):551-6. PubMed ID: 23865353
[TBL] [Abstract][Full Text] [Related]
76. MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients.
Geng JQ; Wang XC; Li LF; Zhao J; Wu S; Yu GP; Zhu KJ
Tumour Biol; 2016 Feb; 37(2):2257-65. PubMed ID: 26358254
[TBL] [Abstract][Full Text] [Related]
77. The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.
Wang Y; Wang Z; Ding Y; Sun F; Ding X
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2405-2407. PubMed ID: 31450913
[TBL] [Abstract][Full Text] [Related]
78. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer.
Reinmuth N; Brandt B; Semik M; Kunze WP; Achatzy R; Scheld HH; Broermann P; Berdel WE; Macha HN; Thomas M
Lung Cancer; 2002 Jun; 36(3):265-70. PubMed ID: 12009236
[TBL] [Abstract][Full Text] [Related]
79. Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125.
Jin C; Yang M; Han X; Chu H; Zhang Y; Lu M; Wang Z; Xu X; Liu W; Wang F; Ju S
J Ovarian Res; 2019 Nov; 12(1):114. PubMed ID: 31767040
[TBL] [Abstract][Full Text] [Related]
80. Clinical significance of CYFRA21-1, Scc-Ag and telomerase activity in serum and pleural effusion of patients with squamous-cell lung cancer.
Liu L; Liu B; Zhu LL; Zhang W; Li Y
Bioanalysis; 2012 Oct; 4(19):2367-74. PubMed ID: 23088463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
